Primary mesenteric sarcomas: Collaborative experience from the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).


Journal

Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 19 09 2020
revised: 06 12 2020
accepted: 08 12 2020
pubmed: 29 12 2020
medline: 11 3 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

Primary mesenteric soft tissue sarcomas (STS) are rare and limited evidence is available to inform management. Surgical resection is challenging due to the proximity of vital structures and a need to preserve enteric function. To determine the overall survival (OS) and recurrence-free survival (RFS) for patients undergoing primary resection for mesenteric STS. The Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) is an intercontinental collaborative comprising specialist sarcoma centers. Data were collected retrospectively for all patients with mesenteric STS undergoing primary resection between 2000 and 2019. Fifty-six cases from 15 institutions were included. The spectrum of pathology was similar to the retroperitoneum, although of a higher grade. R0/R1 resection was achieved in 87%. Median OS was 56 months. OS was significantly shorter in higher-grade tumors (p = .018) and extensive resection (p < .001). No significant association between OS and resection margin or tumor size was detected. Rates of local recurrence (LR) and distant metastases (DM) at 5 years were 60% and 41%, respectively. Liver metastases were common (60%), reflecting portal drainage of the mesentery. Primary mesenteric sarcoma is rare, with a modest survival rate. LR and DM are frequent events. Liver metastases are common, highlighting the need for surveillance imaging.

Sections du résumé

BACKGROUND BACKGROUND
Primary mesenteric soft tissue sarcomas (STS) are rare and limited evidence is available to inform management. Surgical resection is challenging due to the proximity of vital structures and a need to preserve enteric function.
OBJECTIVES OBJECTIVE
To determine the overall survival (OS) and recurrence-free survival (RFS) for patients undergoing primary resection for mesenteric STS.
METHODS METHODS
The Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) is an intercontinental collaborative comprising specialist sarcoma centers. Data were collected retrospectively for all patients with mesenteric STS undergoing primary resection between 2000 and 2019.
RESULTS RESULTS
Fifty-six cases from 15 institutions were included. The spectrum of pathology was similar to the retroperitoneum, although of a higher grade. R0/R1 resection was achieved in 87%. Median OS was 56 months. OS was significantly shorter in higher-grade tumors (p = .018) and extensive resection (p < .001). No significant association between OS and resection margin or tumor size was detected. Rates of local recurrence (LR) and distant metastases (DM) at 5 years were 60% and 41%, respectively. Liver metastases were common (60%), reflecting portal drainage of the mesentery.
CONCLUSION CONCLUSIONS
Primary mesenteric sarcoma is rare, with a modest survival rate. LR and DM are frequent events. Liver metastases are common, highlighting the need for surveillance imaging.

Identifiants

pubmed: 33368277
doi: 10.1002/jso.26353
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1057-1066

Subventions

Organisme : Department of Health
ID : NIHR300175
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Trans-Atlantic RPS Working Group. Management of Primary Retroperitoneal Sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2015;22(1):256-263.
Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii102-iii112.
Casali PG, Abecassis N, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):iv51-iv67.
Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6(1):1-26.
van Houdt WJ, Raut CP, Bonvalot S, Swallow CJ, Haas R, Gronchi A. New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR. Curr Opin Oncol. 2019;31(4):310-316.
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251.
Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350-362.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
MacNeill AJ, Gronchi A, Miceli R, et al. Postoperative morbidity after radical resection of primary retroperitoneal sarcoma. Ann Surg. 2018;267(5):959-964.
Almond LM, Tirotta F, Tattersall H, et al. Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma. Br J Surg. 2019;106(4):395-403.
MacNeill AJ, Miceli R, Strauss DC, et al. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group. Cancer. 2017;123(11):1971-1978.
Dingley B, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas: an update. Expert Rev of Anticancer Ther (2019;19(7):613-631.
Gronchi A, Miceli R, Shurell E, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013;31(13):1649-1655.
Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;21 14(5):1679-1689.
Raut CP, Callegaro D, Miceli R, et al. Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: a study and novel nomogram from TARPSWG. Clin Cancer Res. 2019;25(8):2664-2671.
Almond LM, Gronchi A, Strauss D, Jafri M, Ford S, Desai A. Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. Eur J Surg Oncol. 2018;44(5):571-579.

Auteurs

Hannah L Tattersall (HL)

Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK.

James Hodson (J)

Department of Medical Statistics, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Kenneth Cardona (K)

Department of Surgery, Winship Cancer Institute, Emory University Hospital, Atlanta, GA, USA.

Rachel M Lee (RM)

Department of Surgery, Winship Cancer Institute, Emory University Hospital, Atlanta, GA, USA.

Carolyn Nessim (C)

Department of Surgery, The Ottawa Hospital, University of Ottawa, Ottawa, Canada.

Rebecca Gladdy (R)

Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

Jos Van Der Hage (J)

Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.

Yvonne Schrage (Y)

Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.

William W Tseng (WW)

Division of Breast, Endocrine and Soft Tissue Surgery, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Winan van Houdt (W)

Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Marko Novak (M)

Department of Surgical Oncology, Institute of Oncology, Ljubljana, Slovenia.

Giovanni Grignani (G)

Department of Surgical Oncology, Candiolo Cancer Institute, Candiolo, Italy.

Francesco Tolomeo (F)

Department of Surgical Oncology, Candiolo Cancer Institute, Candiolo, Italy.

Neha Goel (N)

Department of Surgical Oncology, Jackson Memorial Hospital, Miami, USA.

Emily Ryon (E)

Department of Surgical Oncology, Jackson Memorial Hospital, Miami, USA.

David Gyorki (D)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.

Sanjay P Bagaria (SP)

Department of Surgery, Mayo Clinic Jacksonville, Jacksonville, Florida, USA.

Jose A Gonzalez (JA)

Department of Surgery, Sant Pau Hospital, Barcelona, Spain.

Ana B M Arnau (ABM)

Department of Surgery, Sant Pau Hospital, Barcelona, Spain.

Raza Sayyed (R)

Department of Surgery, Patel Hospital, Karachi, Pakistan.

Fabio Tirotta (F)

Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK.

Caroline Evenden (C)

Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK.

Anant Desai (A)

Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK.

Max Almond (M)

Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK.

James Glasbey (J)

Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK.

Marco Fiore (M)

Department of Surgery, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy.

Alessandro Gronchi (A)

Department of Surgery, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy.

Samuel J Ford (SJ)

Midlands Abdominal and Retroperitoneal Sarcoma Unit, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH